Alteogen, 3SBio Agree Pact For ‘Biobetter’ Trastuzumab ADC

Chinese biotech 3SBio has licensed greater China rights to Alteogen’s novel trastuzumab-containing antibody-drug conjugate for breast cancer, in a deal that will expand 3SBio’s biologics pipeline and eventually provide competition in the indication to major firms including Roche.